Familial pancreatic cancer risk: a population-based study in Utah.
Familial
Hereditary cancer
Pancreatic cancer
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
07
03
2019
accepted:
03
06
2019
pubmed:
27
6
2019
medline:
30
9
2020
entrez:
27
6
2019
Statut:
ppublish
Résumé
Pancreas adenocarcinoma (PC) has an undefined hereditary component. We quantified the familial risk of PC among relatives of patients diagnosed with PC and stratified it based on anatomic location of PC and age and sex of the proband. This is a retrospective, population-based, case-control study of PC diagnosed in Utah between 1980 and 2011. The Utah population database and cancer registry were used to identify index patients with PC. The risk of PC in first-degree relatives (FDRs), second-degree relatives (SDRs), and first cousins (FCs) of probands was compared with randomly selected sex- and age-matched population controls. A total of 4,095 patients and 40,933 controls were identified. The relative risk (RR) of PC was 1.76 (95% CI 1.35-2.29) in FDRs, 1.42 (95% CI 1.18-1.7) in SDRs and 1.08 (95% CI 0.95-1.23) in FCs of probands compared to relatives of PC-free controls. The RR were elevated in FDRs (1.96, 95% CI 1.45-2.65), SDRs (1.54, 95% CI 1.19-1.98) and FCs (1.18, 95% CI 1.0-1.64) of female probands. Among probands diagnosed as < 65 years, RR was 2.12 (95% CI 1.37-3.28) in FDRs, 1.94 (95% CI 1.44-2.62) in SDRs, and 1.28 (95% CI 1.0-1.64) in FCs. Overall, the RR for PC was elevated in FDRs regardless of the anatomic location of PC. There is an increased risk of PC in FDR and more distant relatives of patients with PC. Relatives of female patients with PC and patients diagnosed at age < 65 years are at a significantly increased risk of PC.
Identifiants
pubmed: 31240435
doi: 10.1007/s00535-019-01597-3
pii: 10.1007/s00535-019-01597-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1106-1112Subventions
Organisme : NCRR NIH HHS
ID : R01 RR021746
Pays : United States
Organisme : NCI NIH HHS
ID : P01-CA073992
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA042014
Pays : United States
Organisme : NCI NIH HHS
ID : R01-CA040641
Pays : United States
Références
Pancreatology. 2016 Nov - Dec;16(6):1015-1019
pubmed: 27568846
Ann Hum Genet. 1989 Oct;53(4):339-55
pubmed: 2624429
Clin Transl Oncol. 2005 Jun;7(5):189-97
pubmed: 15960930
Int J Cancer. 2013 Nov 15;133(10):2444-53
pubmed: 23661176
Gastroenterology. 2014 Oct;147(4):814-821.e5; quiz e15-6
pubmed: 25042087
JAMA Oncol. 2016 Mar;2(3):340-6
pubmed: 26863281
World J Gastroenterol. 2014 Aug 28;20(32):11182-98
pubmed: 25170203
J Natl Cancer Inst. 2010 Jan 20;102(2):119-26
pubmed: 20068195
Cancer Res. 2004 Apr 1;64(7):2634-8
pubmed: 15059921
Am J Gastroenterol. 2007 Dec;102(12):2696-707
pubmed: 17764494
Int J Cancer. 2010 Sep 1;127(6):1421-8
pubmed: 20049842
Dig Dis Sci. 2016 Dec;61(12):3627-3632
pubmed: 27655103
Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1913-7
pubmed: 23966578
J Chronic Dis. 1985;38(4):289-93
pubmed: 3998045
Therap Adv Gastroenterol. 2017 Mar;10(3):323-336
pubmed: 28246549
Pancreas. 2011 Aug;40(6):974-8
pubmed: 21487321
Ann Oncol. 1999;10 Suppl 4:69-73
pubmed: 10436789
J Natl Cancer Inst. 2001 Apr 18;93(8):640-4
pubmed: 11309441
Int J Epidemiol. 2018 Apr 1;47(2):473-483
pubmed: 29329392
Gut. 2013 Mar;62(3):339-47
pubmed: 23135763
Clin Gastroenterol Hepatol. 2010 Sep;8(9):812-6
pubmed: 20570637
Fam Cancer. 2009;8(2):109-17
pubmed: 18763055
Clin Gastroenterol Hepatol. 2014 Dec;12(12):2078-84.e1-2
pubmed: 24768809
World J Gastroenterol. 2015 Jul 28;21(28):8678-86
pubmed: 26229410
Cancer Treat Rev. 2017 Nov;60:32-43
pubmed: 28869888
Clin Cancer Res. 2001 Mar;7(3):738-44
pubmed: 11297271
Pancreatology. 2018 Jun;18(4):420-428
pubmed: 29709409